Apyx Medical Corp SEC Filing Summary

Apyx Medical Corp, a specialized medical device company, stands out for its innovative Helium Plasma Technology.

Business Overview

Apyx Medical Corp operates in the specialized medical device sector, primarily known for its innovative Helium Plasma Technology and flagship product, Renuvion. The company uses this technology in minimally invasive procedures, often for cosmetic and surgical applications like skin tightening and tissue coagulation. Apyx Medical operates through two key segments:

• Advanced Energy Segment: This segment forms the core of Apyx Medical's operations. It focuses on researching, developing, manufacturing, and commercializing proprietary medical devices, including the Renuvion system. The company invests significantly in R&D, clinical studies, marketing, and professional education for medical practitioners within this segment.
• OEM (Original Equipment Manufacturer) Segment: In this segment, Apyx Medical produces components or finished products for other medical device companies. Direct manufacturing expenses primarily drive costs in this segment. This segment has significant customer concentration.

Risk Factors

Investing in Apyx Medical Corp, like any company, carries inherent risks that investors should carefully consider:

• Macroeconomic Headwinds: Broader economic conditions, including inflation, rising interest rates, and potential economic downturns, can significantly impact the company's financial performance. These conditions can affect consumer spending on elective procedures and overall business costs.
• Liquidity and Debt Management: Maintaining sufficient cash flow to fund ongoing operations and service its secured debt obligations under the Perceptive Credit Agreement is crucial. Any challenges in generating adequate cash could impact financial stability.
• Product Development & Regulatory Success: Future growth depends heavily on the successful development, regulatory approval (e.g., FDA clearance, international certifications), and market adoption of new products and indications for its Helium Plasma Technology, particularly the Renuvion system. Failure to achieve these milestones could hinder revenue growth.
• Significant Product Liability Lawsuits: Ongoing product liability lawsuits specifically related to the Renuvion product pose a major concern. These legal challenges can result in substantial financial penalties, legal expenses, and significant reputational damage, potentially impacting sales and investor confidence.
• Customer Concentration in OEM Segment: A single customer generates a substantial portion of the OEM segment's revenue. The loss of this key customer, or a significant reduction in their orders, could materially and adversely affect the company's financial results for that segment.
• International Market Risks: With a notable percentage of international sales, the company faces risks like currency fluctuations, differing regulatory environments, political instability, and challenges in international distribution and compliance.

Financial Health & Liquidity

Apyx Medical Corp is categorized as a 'smaller reporting company,' trading on the Nasdaq Global Select Market under the ticker APYX. As of mid-2025, the market value of its publicly traded shares (float) was approximately $79.8 million, with about 41.8 million shares outstanding.

To fuel operations and growth, the company has actively raised capital:

• In 2024, they completed a Registered Direct Offering.
• This was followed by an Underwriting Agreement in 2025.

The company also has secured debt under a Perceptive Credit Agreement. Maintaining sufficient cash flow to fund ongoing operations and service its secured debt obligations is crucial for the company's financial health and liquidity management.

Future Outlook & Strategy

Apyx Medical Corp's strategy centers on advancing its Helium Plasma Technology, particularly the Renuvion system. This involves continued research and development, securing regulatory approvals for new applications, and expanding its market reach both domestically and internationally. The company's investment in R&D and global partnerships suggests a focus on innovation and market penetration. The company's operational management prioritizes cybersecurity and global reach through ventures (e.g., in China), supporting its strategic goals.

This overview provides a foundational understanding of Apyx Medical Corp's business model, financial framework, and the significant risks it navigates. For a complete investment decision, a thorough review of the full 10-K, including detailed financial statements, specific growth strategies, and the full scope of legal and regulatory disclosures, is always recommended.